fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Immunotherapy with nivolumab increases survival in advanced Hodgkin lymphoma

Written by | 17 Oct 2024

An investigative immunotherapy regimen for advanced Hodgkin lymphoma has increased the survival rate from 80 percent to 92 percent, researchers reported on Oct. 17, 2024 in the NEJM/New… read more.

ASCO: Neoadjuvant therapy shows superiority for resectable stage III melanoma

Written by | 27 Jun 2024

ASCO: In resectable stage III melanoma, treatment with the immunotherapies ipilimumab and nivolumab before lymph nodes are surgically removed is more effective than treatment with nivolumab after the… read more.

Perioperative nivolumab shows significant efficacy in lung cancer treatment

Written by | 18 May 2024

When compared with pre-surgical (neoadjuvant) chemotherapy only, adding perioperative immunotherapy before and after surgery significantly improves event-free survival in patients with resectable early-stage non-small cell lung cancer (NSCLC),… read more.

FDA approves Opdivo (nivolumab), plus cisplatin and gemcitabine, for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma – BMS

Written by | 17 Mar 2024

Bristol Myers Squibb announced that the FDA approved Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial… read more.

FDA acceptance of U.S. and EU regulatory filings for neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo in resectable non-small cell lung cancer – BMS

Written by | 12 Feb 2024

Bristol Myers Squibb announced two regulatory acceptances for applications for; i. neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and ii. adjuvant Opdivo for the perioperative treatment of… read more.

Nivolumab appears to benefit patients with stage III lung cancer

Written by | 12 Aug 2023

Among patients with resectable stage IIIA or IIIB NSCLC (non–small-cell lung cancer), those treated with neoadjuvant nivolumab plus chemotherapy have achieved a higher level of complete response and… read more.

Nivolumab study supports use of immune checkpoint inhibitors in advanced skin cancer

Written by | 25 Oct 2022

Researchers report that patients with advanced cutaneous squamous cell carcinoma, a skin cancer and one of the most frequent malignancies worldwide, benefit from treatment with the immune checkpoint… read more.

CHMP recommends Opdivo for the adjuvant treatment of adults with muscle-invasive urothelial carcinoma – BMS

Written by | 6 Jul 2022

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) for the… read more.

Study introduces new strategy to treat advanced liver cancer

Written by | 19 Nov 2021

Advanced liver cancer, or hepatocellular carcinoma (HCC), currently has limited treatment options and poor prognosis • A recent study introduces a new approach to treat advanced HCC by… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.